In a subgroup analysis of the ATTRACTION‐2 trial, in which the HER2 status was not determined, the efficacy of nivolumab was determined to be consistent in gastric cancer, regardless of prior trastuzumab use.26 The gene discussed is ERBB2; the disease is gastric cancer.